Core Viewpoint - Xinnoway is a leading company in the functional food industry in China, with strong technical capabilities and market competitiveness in research, production, and sales of functional foods [1] Group 1: Business Performance - In Q3 2025, Xinnoway reported revenue of 1.593 billion yuan, ranking 11th among 47 companies in the industry, with the industry leader, Puluo Pharmaceutical, generating 7.764 billion yuan [2] - The net profit for the same period was -310 million yuan, placing the company at the bottom of the industry rankings, while the top performer, Zhejiang Pharmaceutical, achieved a net profit of 867 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Xinnoway's debt-to-asset ratio was 32.94%, higher than the previous year's 16.97% and above the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 39.68%, down from 42.99% year-on-year but still above the industry average of 35.38% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 3.45% to 16,400, while the average number of circulating A-shares held per account decreased by 3.34% to 76,000 [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [5] Group 4: Future Outlook - According to Shenwan Hongyuan, Xinnoway's revenue is expected to grow, with a projected income of 2.19 billion yuan in 2025, 2.49 billion yuan in 2026, and 2.8 billion yuan in 2027, alongside a gradual improvement in net profit [6] - Dongwu Securities highlighted a slight revenue increase in H1 2025, with significant profit decline attributed to rising expense ratios, while emphasizing the potential of new drug developments [6]

作为百事可乐、可口可乐、红牛等国际饮料巨头的全球供应商，新诺威正积极寻求超越其传统功能性原 料和保健食品业务的发展路径。 然而在业绩层面，公司却面临不小的压力。尽管前三季度营业收入实现微增，净利润却出现大幅下滑， 亏损幅度高达567.47%，归母净利润与扣非净利润更是录得首次三季报亏损。 当前，新诺威一方面面临支柱业务增长乏力，另一方面新业务尚未形成有效支撑，处于"青黄不接"的阶 段。其频繁收购的举措也引发市场关注，所收购的创新药资产仍处于投入期，无法贡献利润，使得公司 整体盈利持续承压。新诺威将如何破解当前困局，成为市场关注的焦点。 就上述问题，《华夏时报》记者向新诺威致函询问，截至发稿未获回复。 今年以来，新诺威动作频频，一方面通过收购控股股东资产向创新药领域拓展，另一方面推进赴港IPO 进程，力求业务转型与资本运作齐头并进。 陷"增收不增利"困局 新诺威核心业务涵盖功能性原料、保健食品、特医食品的研发、生产与销售。其功能性原料产品主要包 括咖啡因、阿卡波糖、无水葡萄糖等；保健食品以"果维康"系列维生素C含片、B族维生素含片为代 表；特医食品则聚焦于非全营养配方产品。 公司收入几乎全部来源于功能性原料与保 ...

Core Insights - A total of 490 stocks in the Shanghai and Shenzhen markets have experienced net outflows of main funds for five consecutive days or more as of October 29 [1] - The stock with the longest continuous net outflow is Zhongju Gaoxin, with 31 days of outflows, followed by Hengshen New Materials with 21 days [1] - The largest total net outflow amount is from China Merchants Bank, with a cumulative outflow of 3.093 billion yuan over 12 days [1] Group 1: Stocks with Longest Net Outflows - Zhongju Gaoxin has seen net outflows for 31 days, with a total outflow of 559 million yuan and a cumulative decline of 6.91% [1] - Hengshen New Materials has recorded net outflows for 21 days, totaling 197 million yuan, with a decline of 9.80% [3] - China Merchants Bank has the highest net outflow amount of 3.093 billion yuan over 12 days, with a net outflow ratio of 6.98% and a cumulative increase of 1.65% [1] Group 2: Other Notable Stocks - Guotai Junan has experienced net outflows for 10 days, amounting to 1.877 billion yuan, with a net outflow ratio of 7.89% and a cumulative increase of 2.70% [1] - Shengbang Co. has seen net outflows for 12 days, totaling 1.826 billion yuan, with a net outflow ratio of 9.52% and a cumulative decline of 10.65% [1] - Huajian Group has recorded net outflows for 6 days, with a total outflow of 1.713 billion yuan and a significant decline of 40.29% [1] Group 3: Stocks with Significant Outflow Ratios - Jianan Intelligent has the highest net outflow ratio at 14.74%, with a decline of 2.98% over the past 5 days [1] - Other notable stocks with high outflow ratios include Huayi Development at 11.91% and Pianzaihuang at 11.84% [1] - The overall trend indicates a significant outflow of funds from various sectors, reflecting investor sentiment and market conditions [1]

Group 1 - Newnow (300765.SZ) reported its Q3 2025 results, with 18 institutional investors holding a total of 1.144 billion shares, representing 81.42% of the total share capital [1] - The top ten institutional investors collectively hold 81.17% of the shares, with a decrease of 0.47 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 10 funds increased their holdings, including Huatai-PineBridge Innovation Medicine Mixed A and ICBC Frontier Medical Stock A, with an increase rate of 0.60% [2] - Three public funds reduced their holdings, including China Europe Medical Health Mixed A, with a decrease rate of 0.37% [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.23% [2]

Group 1: Kingsoft Office - Kingsoft Office reported a revenue of 1.521 billion yuan in Q3 2025, a year-on-year increase of 25.33% [1][2] - The net profit attributable to shareholders for Q3 2025 was 431 million yuan, reflecting a growth of 35.42% year-on-year [1][2] - For the first three quarters of 2025, the total revenue reached 4.178 billion yuan, up 15.21% year-on-year, while net profit was 1.178 billion yuan, an increase of 13.32% [1][2] Group 2: Ying Shi Innovation - Ying Shi Innovation achieved a revenue of 2.940 billion yuan in Q3 2025, marking a significant growth of 92.64% year-on-year [4] - The net profit attributable to shareholders for Q3 2025 was 272 million yuan, a decrease of 15.90% compared to the previous year [4][5] - For the first three quarters, the company reported a total revenue of 6.611 billion yuan, up 67.18%, while net profit was 792 million yuan, down 5.95% year-on-year [4][5] Group 3: Aier Eye Hospital - Aier Eye Hospital reported a revenue of 5.977 billion yuan in Q3 2025, a year-on-year increase of 3.83% [6][7] - The net profit attributable to shareholders for Q3 2025 was 1.064 billion yuan, reflecting a decline of 24.12% year-on-year [6][7] - For the first three quarters, the total revenue reached 17.484 billion yuan, up 7.25%, while net profit was 3.115 billion yuan, down 9.76% [6][7] Group 4: Hengrui Medicine - Hengrui Medicine reported a revenue of 7.427 billion yuan in Q3 2025, a year-on-year increase of 12.72% [8][10] - The net profit attributable to shareholders for Q3 2025 was 1.301 billion yuan, reflecting a growth of 9.53% year-on-year [8][10] - For the first three quarters, the total revenue reached 23.188 billion yuan, up 14.85%, while net profit was 5.751 billion yuan, an increase of 24.50% [8][10] Group 5: Victory Technology - Victory Technology achieved a revenue of 5.086 billion yuan in Q3 2025, marking a year-on-year increase of 78.95% [11][12] - The net profit attributable to shareholders for Q3 2025 was 1.102 billion yuan, reflecting a substantial growth of 260.52% year-on-year [11][12] - For the first three quarters, the company reported a total revenue of 14.117 billion yuan, up 83.40%, while net profit was 3.245 billion yuan, an increase of 324.38% [11][12] Group 6: Southern Airlines - Southern Airlines reported a revenue of 51.374 billion yuan in Q3 2025, a year-on-year increase of 3.01% [13][14] - The net profit attributable to shareholders for Q3 2025 was 3.840 billion yuan, reflecting a growth of 20.26% year-on-year [13][14] - For the first three quarters, the total revenue reached 137.665 billion yuan, up 2.23%, while net profit was 23.070 billion yuan, an increase of 17.40% [13][14] Group 7: Ningbo Bank - Ningbo Bank reported a revenue of 17.816 billion yuan in Q3 2025, a year-on-year increase of 9.19% [16][17] - The net profit attributable to shareholders for Q3 2025 was 7.673 billion yuan, reflecting a growth of 8.71% year-on-year [16][17] - For the first three quarters, the total revenue reached 54.976 billion yuan, up 8.32%, while net profit was 22.445 billion yuan, an increase of 8.39% [16][17] Group 8: Guizhou Moutai - Guizhou Moutai announced the resignation of Chairman Zhang Deqin due to work adjustments, with a new chairman to be elected soon [19] Group 9: Baosteel - Baosteel reported a revenue of 167.51 billion yuan in Q3 2025, a year-on-year increase of 14.29% [20][21] - The net profit attributable to shareholders for Q3 2025 was 812.45 million yuan, reflecting a return to profitability [20][21] - For the first three quarters, the total revenue reached 480.8 billion yuan, down 3.58%, while net profit was 2.33 billion yuan [20][21] Group 10: China Aluminum - China Aluminum reported a revenue of 601.24 billion yuan in Q3 2025, a year-on-year decrease of 4.66% [22][23] - The net profit attributable to shareholders for Q3 2025 was 38.01 billion yuan, reflecting a significant increase of 90.31% year-on-year [22][23] - For the first three quarters, the total revenue reached 1,765.16 billion yuan, up 1.57%, while net profit was 108.72 billion yuan, an increase of 20.65% [22][23] Group 11: Northern Rare Earth - Northern Rare Earth reported a revenue of 114.25 billion yuan in Q3 2025, a year-on-year increase of 33.32% [25][26] - The net profit attributable to shareholders for Q3 2025 was 610 million yuan, reflecting a growth of 69.48% year-on-year [25][26] - For the first three quarters, the total revenue reached 302.92 billion yuan, up 40.50%, while net profit was 1.541 billion yuan, an increase of 280.27% [25][26] Group 12: Hengli Petrochemical - Hengli Petrochemical reported a revenue of 534.96 billion yuan in Q3 2025, a year-on-year decrease of 17.98% [27] - The net profit attributable to shareholders for Q3 2025 was 19.72 billion yuan, reflecting a significant increase of 81.47% year-on-year [27] - For the first three quarters, the total revenue reached 1,573.84 billion yuan, down 11.46%, while net profit was 50.23 billion yuan, a slight decrease of 1.61% [27] Group 13: High Energy Environment - High Energy Environment is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and competitiveness [28] Group 14: Guangyun Technology - Guangyun Technology plans to acquire a 36.4652% stake in Chengdu Lingxuan Precision Machinery Co., Ltd. for 240 million yuan, gaining control over the company [29] Group 15: Zhongxin Metal - Zhongxin Metal reported a revenue of 39.807 billion yuan in Q3 2025, a year-on-year increase of 29.21% [32] - The net profit attributable to shareholders for Q3 2025 was 877 million yuan, reflecting a growth of 43.74% year-on-year [32] - For the first three quarters, the total revenue reached 1,034.64 billion yuan, up 8.84%, while net profit was 2.326 billion yuan, an increase of 35.47% [32]

智通财经APP讯，石药集团(01093)发布石药创新(300765.SZ)前三季度业绩，该集团取得收入15.93亿 元，同比增加7.71%，归属于上市公司股东的净亏损2404.89万元，基本每股亏损0.0173元。 ...

Core Insights - The company reported a revenue of 1.593 billion yuan for the first three quarters, representing a year-on-year increase of 7.71% [1] - The net loss attributable to shareholders was 24.0489 million yuan, with a basic loss per share of 0.0173 yuan [1] Financial Performance - Revenue: 1.593 billion yuan, up 7.71% year-on-year [1] - Net Loss: 24.0489 million yuan [1] - Basic Loss per Share: 0.0173 yuan [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 CSPC PHARMACEUTICAL GROUP LIMITED 石藥集團有限公司 （股份代號：1093） （於香港註冊成立之有限公司） 石 藥 創 新 製 藥 股 份 有 限 公 司 截 至2025年9月30日 止 九 個 月 之 未 經 審 核 財 務 資 料 按 深 圳 證 券 交 易 所 之 相 關 規 定，石 藥 集 團 有 限 公 司（「本 公 司」）附 屬 公 司 石 藥 創 新 製 藥 股 份 有 限 公 司（「石 藥 創 新」，其 股 份 於 深 圳 證 券 交 易 所 創 業 板 上 市（股 票 代 碼：300765））， 已 於2025年10月27日 發 佈 其 截 至2025年9月30日 止 九 ...

Core Viewpoint - Newell reported a revenue of 543 million yuan for Q3 2025, marking a year-on-year increase of 7.18%, but faced a net loss attributable to shareholders of 21.3 million yuan, a significant decline of 1025.45% compared to the previous year [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 1.593 billion yuan, reflecting a year-on-year growth of 7.71% [1] - The net loss attributable to shareholders for the first three quarters was 24.0489 million yuan, which represents a year-on-year decline of 117.26% [1]

智通财经APP讯，新诺威(300765.SZ)发布2025年三季度报告，该公司前三季度营业收入为15.93亿元， 同比增长7.71%。归属于上市公司股东的净亏损为2404.89万元。归属于上市公司股东的扣除非经常性损 益的净亏损为6482.09万元。基本每股亏损为0.0173元。 ...